AUSTIN, Texas & NEW YORK–(BUSINESS WIRE)–BrainCheck Inc., a cognitive workflow platform, today highlighted the publication of a peer-reviewed study design paper for PREDICTOM — the large-scale European Alzheimer’s early detection initiative in which BrainCheck Assess is serving as a cognitive assessment tool. The paper, published in The Journal of Prevention of Alzheimer’s Disease, details the full protocol for a novel AI-driven screening platform designed to bring Alzheimer’s diagnostics into the home and community care setting.
PREDICTOM (Prediction of Alzheimer’s Disease using an AI-driven Screening Platform) is an observational, prospective cohort study enrolling 4,000 adults aged 50 and older across seven countries: Norway, the United Kingdom, France, Germany, Switzerland, Spain, and Belgium.
The study, which runs from November 2023 through October 2027, is designed to test whether an AI-driven combination of established and novel biomarkers — collected at home or in primary care — can accurately identify individuals at elevated risk for Alzheimer’s disease and be integrated into a practical, scalable clinical pathway. In Level 1, participants complete fully home-based assessments, including BrainCheck Assess, online hearing screening, eye-tracking, and at-home biofluid collection via finger-stick blood and saliva. An AI risk stratification algorithm then identifies high-risk individuals for more comprehensive in-clinic assessments, culminating in confirmatory diagnostic evaluation using cerebrospinal fluid analysis or amyloid PET.
The publication of this study design is a meaningful milestone, establishing the scientific framework that will guide data collection and AI model development through the study’s 2027 completion, and against which future clinical outcomes will be evaluated.
“With disease-modifying therapies now approved for early-stage Alzheimer’s, the window for meaningful intervention is earlier than ever, and that makes scalable, accessible screening tools absolutely critical,” said Mary Patterson, Vice President of Clinical Operations at BrainCheck. “PREDICTOM’s approach, using home-based digital assessment to triage a large population before more resource-intensive diagnostics are applied, is exactly the kind of model health systems need. We’re proud to be part of building that evidence base.”
For more information about BrainCheck, visit www.braincheck.com.
Citation
Brem AK, Khan Z, Radermacher J, et al. Screening for Alzheimer’s disease in the community using an AI-driven screening platform: design of the PREDICTOM study. The Journal of Prevention of Alzheimer’s Disease. 2026;13(5):100545. doi:10.1016/j.tjpad.2026.100545.
About BrainCheck
BrainCheck is a cognitive workflow platform that helps healthcare organizations operationalize a more standardized, repeatable approach to cognitive evaluation and follow-up. Built around BrainCheck Assess™—its flagship FDA Class II digital cognitive assessment—the platform connects key steps across the cognitive care workflow in a single solution, from screening and assessment through interpretation, care planning, and longitudinal monitoring.
BrainCheck is used by more than 500 healthcare organizations nationwide, including Kitwood Health, Bon Secours, UPMC, and Springfield Clinic, as well as 46 research hospitals, including The University of Texas at Austin and Stanford University. Clinicians use BrainCheck’s clinical evaluation tools, including validated screeners and assessments, and care planning tools, to build tailored protocols.
BrainCheck is intended to support clinical decision-making and is not designed to function as a stand-alone diagnostic tool.
Contacts
Media Contact
BrainCheck Marketing
[email protected]
